CD40 and rheumatoid arthritis: Accordingly, the Fc-silent IgG1(N297A) anti-CD40 antibody Iscalimab was found to be well tolerated and triggered no signs of thromboembolic events in a phase I study with rheumatoid arthritis (RA) patients dosed with up to 30 mg/kg [52]; (ClinicalTrials.gov Identifier: NCT02089087, accessed on 24 October 2022).